Treatment Response Trajectories and Their Antecedents in Recent-Onset Psychosis
Authors:
- Stephen Z. LevineSLStephen Z. Levine
- Jonathan RabinowitzJRJonathan Rabinowitz
- Michael CaseMCMichael Case
- Haya Ascher-SvanumHAHaya Ascher-Svanum
- 1 August 2010
- journal article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 30 (4) , 446-449
Abstract
The extent of heterogeneity in antipsychotic treatment response for over extended period is unclear. This study aimed to quantify treatment response trajectories and their characteristics up to 2 years in recent-onset psychosis. Participants were from a double-blind randomized controlled trial of recent-episode psychosis (N = 263). Recurrent Positive and Negative Syndrome Scale (PANSS) administrations were used to index treatment response trajectories for up to 2 years. Trajectories were calculated with mixed-mode latent class regression modeling from which groups were derived. Group differences were examined on sex, age of first admission, duration of untreated psychosis, premorbid functioning, diagnoses of substance abuse and schizophrenia, and cognitive functioning. Five trajectories based on PANSS total scores were identified at 2 years. In the trajectory group (23.1%) with the most improvement, approximately 62% met the PANSS 30% change criteria. Logistic regression modeling indicated that membership in the trajectory with the most improvement was significantly (P < 0.05) predicted by absence of a diagnosis of schizophrenia, better premorbid functioning, and higher cognitive scores. Membership in the trajectory with the least improvement was significantly predicted by higher PANSS baseline scores. Based on clinical trial data, treatment response in early episode psychosis seems to be characterized by amelioration and ongoing change. Premorbid functioning, cognitive functioning, and early symptom severity have prognostic value in predicting treatment response trajectories. Across trajectory studies, approximately 16% of patients experience a dramatic treatment response trajectory characterized by approximately a 60% to 80% symptom reduction.Keywords
This publication has 16 references indexed in Scilit:
- Premorbid functioning and treatment response in recent-onset schizophreniaThe British Journal of Psychiatry, 2006
- Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode PsychosisBiological Psychiatry, 2006
- Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-AnalysisAmerican Journal of Psychiatry, 2005
- Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term TrialAmerican Journal of Psychiatry, 2005
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidolSchizophrenia Research, 2004
- Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus HaloperidolAmerican Journal of Psychiatry, 2003
- Sex Differences in the Risk of SchizophreniaArchives of General Psychiatry, 2003
- Age at onset and gender of schizophrenic patients in relation to neuroleptic resistanceAmerican Journal of Psychiatry, 1997
- Measurement of Premorbid Adjustment in Chronic SchizophreniaSchizophrenia Bulletin, 1982